Skip to main content
SpringerLink
Log in

Psychopharmakotherapie – klinisch-empirische Grundlagen

  • Chapter
  • First Online:
Psychiatrie, Psychosomatik, Psychotherapie

Part of the book series: Springer Reference Medizin ((SRM))

  • 35k Accesses

Zusammenfassung

In diesem Kapitel werden zum einen die Grundlagen der klinischen Prüfung von Psychopharmaka, v. a. betreffend Studiendesign und statistischer Auswertemethoden, dargestellt. Besonderen Wert wird auch auf das neue Gebiet der Metaanalysen gelegt. Zum anderen werden die großen Substanzklassen dargestellt, sodass der Leser einen Überblick über die unterschiedlichen psychopharmakologischen Behandlungsoptionen erhält. Hierbei wird auf eine umfassende Darstellung Wert gelegt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Al-Sukhni M, Maruschak NA, McIntyre RS (2015) Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 14:1291–1304

    Article  CAS  PubMed  Google Scholar 

  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association of the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267–272

    Article  Google Scholar 

  • Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8:238–249

    Article  CAS  PubMed  Google Scholar 

  • Andreasen NC (1984a) Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City

    Google Scholar 

  • Andreasen NC (1984b) Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City

    Google Scholar 

  • Ashton H. Benzodiazepine Wirkungsweise und therapeutischer Entzug. Überarbeitete Fassung 2002. http://www.benzo.org.uk/german/bzcha01.htm#8. Zugegriffen am 19.08.2013

  • Auguet M, Clostre F, De Feudis FV (1986) Effects of antidepressants on receptor-activated and Ca2+− activated contractions of rabbit isolated aorta. Gen Pharmacol 17:607–610

    Article  CAS  PubMed  Google Scholar 

  • Baastrup PC, Poulsen JC, Schou M et al (1970) Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 15:326–330

    Article  Google Scholar 

  • Baldwin DS, Loft H, Dragheim M (2012) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 22:482–491

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Tharmanathan P, Volz HP et al (2009) The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259:172–185

    Article  PubMed  Google Scholar 

  • Bauer M, Pfennig A, Severus E et al (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–385

    Article  PubMed  Google Scholar 

  • Bech P (1978) Depressive symptomatology and drug response. Commun Psychopharmacol 2:409–418

    CAS  PubMed  Google Scholar 

  • Benkert O, Hippius H (2014) Kompendium der psychiatrischen Pharmakotherapie, 10. Aufl. Springer, Berlin/Heidelberg

    Google Scholar 

  • Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev (1):CD001190.

    Google Scholar 

  • Birks JS, Chong LY, Grimley Evans J (2015) Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. Sep 22;9:CD001191

    Google Scholar 

  • Borbely AA, Mattmann P, Loepfe M et al (1985) Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 4:189–194

    CAS  PubMed  Google Scholar 

  • Boulenger JP, Loft H, Flora I (2012) A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Psychopharmacology 26:1408–1416

    Article  CAS  Google Scholar 

  • Bowden CL, Calabrese JR, McElroy SL et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481–489

    Article  CAS  PubMed  Google Scholar 

  • Bowden CL, Calabrese JR, Sachs G (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392–400

    Article  CAS  PubMed  Google Scholar 

  • Braquet P (1987) The ginkgolides: potent platelet-activating factor antagonists’ isolated from Ginkgo biloba L. chemistry, pharmacology and clinical applications. Drugs Fut 12:643–699

    Article  Google Scholar 

  • Brondino N, De Silvestri A, Re S (2013) A systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: from ancient tradition to modern-day medicine. Evid Based Complement Alternat Med 2013:915691

    Article  PubMed  PubMed Central  Google Scholar 

  • Calabrese JR, Bowden CL, Sachs G et al (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013–1024

    Article  CAS  PubMed  Google Scholar 

  • Calabrese JR, Goldberg JF, Ketter TA et al (2006) Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 59:1061–1064

    Article  CAS  PubMed  Google Scholar 

  • Castells X, Ramos-Quiroga JA, Bosch R et al (2011a) Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. Cochrane Database Syst Rev (6):CD007813

    Google Scholar 

  • Castells X, Ramos-Quiroga JA, Rigau D et al (2011b) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157–169

    Google Scholar 

  • Cipriani A, Furukawa TA, Geddes JR et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758

    Article  CAS  PubMed  Google Scholar 

  • CIPS, Collegium Internationale Psychiatriae Scalarum (Hrsg) (2015) Internationale Skalen für Psychiatrie. Hogrefe, Göttingen

    Google Scholar 

  • Cross National Collaborative Panic Study (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 160:191–202

    Article  Google Scholar 

  • Cunill R, Castells X, Tobias A et al (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 22:961–969

    CAS  PubMed  Google Scholar 

  • Cunill R, Castells X, Tobias A et al (2016) Efficacy safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology (Berl) 233:187–197

    Article  CAS  Google Scholar 

  • Davis JM, Schaffer CB, Killian GA et al (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70–87

    Article  CAS  PubMed  Google Scholar 

  • DGPPN, BÄK, KBV et al (Hrsg) (2015) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression, 2. Aufl.

    Google Scholar 

  • Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160:217–222

    Article  CAS  PubMed  Google Scholar 

  • Downing RW, Rickels K (1985) Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 72:522–528

    Article  CAS  PubMed  Google Scholar 

  • Du J, Gray NA, Falke C et al (2003) Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann N Y Acad Sci 1003:378–380

    Article  CAS  PubMed  Google Scholar 

  • Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763

    Article  PubMed  Google Scholar 

  • Farrimond L, Roberts E, McShane R (2012) Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMI Open 2, e000917

    Article  Google Scholar 

  • Frank E, Kupfer DJ, Perel JM et al (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093–1099

    Article  CAS  PubMed  Google Scholar 

  • Fritz RR, Malek-Ahmadi P et al (1983) Tranylcypromine lowers human platelet MAO B activity but not concentration. Biol Psychiatry 18:685–694

    CAS  PubMed  Google Scholar 

  • Gentil V, Alevizos B, Felix-Gentil M et al (1978) Single-dose effects of tranylcypromine on psychophysiological measures in normals. Br J Clin Pharmacol 5:536–538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gianoulakis C (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4:39–50

    Article  CAS  PubMed  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR et al (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432–441

    Article  CAS  PubMed  Google Scholar 

  • Graham J, Banaschewski T, Buitelaar J et al (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17–37

    Article  CAS  PubMed  Google Scholar 

  • Greil W, Kleindienst N (1999a) The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 14:277–281

    Article  CAS  PubMed  Google Scholar 

  • Greil W, Kleindienst N (1999b) Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 14:283–285

    Article  CAS  PubMed  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N et al (1997) Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomised study. J Affect Disord 43:151–161

    Article  CAS  PubMed  Google Scholar 

  • Grunze H, Bauer M (2012) Medikamente zur Behandlung bipolar affektiver Störungen. In: Gründer G, Benkert O (Hrsg) Handbuch der psychiatrischen Pharmakotherapie, 2. Aufl. Springer, Berlin, S 629–657

    Google Scholar 

  • Grunze H, Vieta E, Goodwin GM et al (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14:154–219

    Article  PubMed  Google Scholar 

  • Gual A, He Y, Torup L, van den Brink W et al (2013) A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 23:1432–1442

    Article  CAS  PubMed  Google Scholar 

  • Hajak G, Müller WE, Wittchen HU et al (2003) Abuse and dependence potential for the nonbenzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378

    Article  CAS  PubMed  Google Scholar 

  • Hasan A, Falkai P, Wobrock T et al (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378

    Article  PubMed  Google Scholar 

  • Hatta K, Sato K, Hamakawa H et al (2009) Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Res 113:49–55

    Article  Google Scholar 

  • Hazell PL, Kohn MR, Dickson R et al (2011) Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord 15:674–683

    Article  PubMed  Google Scholar 

  • Heuser I, Förstl H (2012) Antidementiva. In: Gründer G, Benkert O (Hrsg) Handbuch der psychiatrischen Pharmakotherapie, 2. Aufl. Springer, Berlin, S 713–731

    Google Scholar 

  • Howard R, McShane R, Lindesay J et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366:893–903

    Article  CAS  PubMed  Google Scholar 

  • Huedo-Medina TB, Kirsch I, Middlemass J et al (2012) Effektiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 345. doi:10.1136/bmj.e8343

    Google Scholar 

  • Ihl R, Frölich L, Winblad B et al (2011) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry 12:2–32

    Article  PubMed  Google Scholar 

  • Janssens D, Michiels C, Delaive E et al (1995) Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and Bilobalide. Biochem Pharmacol 50:991–999

    Article  CAS  PubMed  Google Scholar 

  • Janssens D, Remacle J, Drieu K et al (1999) Protection of mitochondrial respiration activity by Bilobalide. Biochem Pharmacol 58:109–119

    Article  CAS  PubMed  Google Scholar 

  • Janssens D, Delaive E, Remacle J et al (2000) Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity. Fundam Clin Pharmacol 14:193–201

    Article  CAS  PubMed  Google Scholar 

  • Kane JM, Woerner M, Borenstein M et al (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258

    CAS  PubMed  Google Scholar 

  • Kasper S, Buchkremer G, Dilling H et al (Hrsg) (1994) Depressive Storungen erkennen und behandeln. Karger, Basel Freiburg

    Google Scholar 

  • Kasper S, Möller HJ (2011) Psychopharmakotherapie – Klinisch-empirische Grundlagen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie, Psychosomatik, Psychotherapie, Bd 1, 4. Aufl. Springer, Heidelberg, S 731–766

    Chapter  Google Scholar 

  • Kasper S, Olié JP (2002) A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 17(Suppl 3):331–340

    Article  PubMed  Google Scholar 

  • Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27:215–223

    Article  PubMed  Google Scholar 

  • Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276

    Article  CAS  PubMed  Google Scholar 

  • Keller MB, Trivedi MH, Thase ME (2007a) The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry 62:1371–1379

    Article  CAS  PubMed  Google Scholar 

  • Keller MB, Trivedi MH, Thase ME et al (2007b) The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 68:1246–1256

    Article  CAS  PubMed  Google Scholar 

  • Kiefer F, Mann K (2010) Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des 16:2098–2102

    Article  CAS  PubMed  Google Scholar 

  • Kiefer F, Soyka M (2012) Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen. In: Gründer G, Benkert O (Hrsg) Handbuch der psychiatrischen Pharmakotherapie, 2. Aufl. Springer, Berlin, S 733–7491

    Google Scholar 

  • Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213

    Article  PubMed  Google Scholar 

  • Kissling W (1991) Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Berlin/Heidelberg/New York

    Book  Google Scholar 

  • Kocsis JH, Thase ME, Trivedi MH et al (2007) Preventention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 68:1014–1023

    Article  CAS  PubMed  Google Scholar 

  • Koesters M, Becker T, Kilian R et al (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744

    Article  CAS  PubMed  Google Scholar 

  • Kraus JE, Sheitman BB, Cook A et al (2005) Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. J Clin Psychiatry 66:1564–1568

    Article  CAS  PubMed  Google Scholar 

  • Kupfer DJ (1991) Lessons to be learned from long-term treatment of aff ective disorders: Potential utility in panic disorder. J Clin Psychiatry 52 (Suppl 2): 12–16

    Google Scholar 

  • Lang F, Hoerr R, Noeldner M et al (2013) Ginkgo biloba extract EGb 761: from an ancient Asian plant to a modern European herbal medicine product. In: Wagner H, Ulrich-Merzenich G (Hrsg) Evidence and rational based research on Chinese drugs. Springer, Wien, S 431–470

    Google Scholar 

  • Lau J, Ioannidis JPA, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826

    Article  CAS  PubMed  Google Scholar 

  • Laux G, Ulrich S (2006) Tranylcypromin. PPT 13:130–144

    Google Scholar 

  • Laux G, VIVALDI Study Group (2012) The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry 45:284–291

    Article  CAS  PubMed  Google Scholar 

  • Laux G, Becker T, Müller U (2002) Indikationen (von Tranylcypromin). In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka. Ein Therapiehandbuch, Bd 3, Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Springer, Wien/New York, S 489–507

    Google Scholar 

  • Laux G, Huttner NA, VIVALDI Study Group (2014) Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract 18:86–96

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Barnes TR, Kissling W et al (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222

    Article  PubMed  Google Scholar 

  • Leucht S, Corves C, Arbter D et al (2009) Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 282:951–962

    Article  CAS  Google Scholar 

  • Linde K, Mulrow CD, Berner M et al (2005) St John’s wort for depression. Cochrane Database Syst Rev (2)

    Google Scholar 

  • Lockhart IA, Mitchell SA, Kelly S (2009) Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the ‚real-world‘ evidence. Dement Geriatr Cogn Disord 28:389–403

    Article  CAS  PubMed  Google Scholar 

  • Loy C, Schneider L (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 1, CD001747

    Google Scholar 

  • Mahableshwarkar AR, Zajecka J, Jacobson W et al (2015) A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 8:2025–2037

    Article  CAS  Google Scholar 

  • Maneeton N, Maneeton B, Eurviriyanukul K et al (2013) Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine. Drug Des Devel Ther 7:1053–1062

    Article  PubMed  PubMed Central  Google Scholar 

  • Mann K, Bladström A, Torup L (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73:706–713

    Article  CAS  PubMed  Google Scholar 

  • McCue R, Waheed R, Urcuyo L et al (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 189:433–440

    Article  Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev. Apr 19;(2):CD003154

    Google Scholar 

  • Meeker AS, Herink MC, Haxby DG et al (2015) The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 4:21

    Article  PubMed  PubMed Central  Google Scholar 

  • Mészáros A, Czobor P, Bálint S et al (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147

    Article  PubMed  CAS  Google Scholar 

  • Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R et al (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1–40). Brain Res 958:210–221

    Article  CAS  PubMed  Google Scholar 

  • Möller HJ (1990) Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K (Hrsg) Leitlinien neuroleptischer Therapie. Springer, Berlin/Heidelberg/New York, S 97–115

    Chapter  Google Scholar 

  • Möller HJ (2001) Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms. Eur Arch Psychiatry Clin Neurosci 251:217–224

    Article  PubMed  Google Scholar 

  • Möller HJ (2004) Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 5:9–19

    Article  PubMed  Google Scholar 

  • Murphy BP, Chung YC, Park TW et al (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88:5–25

    Article  PubMed  Google Scholar 

  • Neuvonen PJ, Pohjola-Sintonen S, Tacke U et al (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342:1419

    Article  CAS  PubMed  Google Scholar 

  • NICE (National Institute for Clinical Excellence) (2003) Core interventions in the treatment of schizophrenia. NICE, London. www.nice.org.uk

  • Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85:67–76

    Article  CAS  PubMed  Google Scholar 

  • Nutt DJ (2009) Beyond psychoanaleptics – can we improve antidepressant drug nomenclature? J Psychopharmacol 23:343–345

    Article  CAS  PubMed  Google Scholar 

  • O’Donnell T, Rotzinger S, Nakashima TT et al (2003) Chronic lithium and sodium valproate both decrease the concentration of myoinositol and increase the concentration of inositol monophosphates in rat brain. Eur Neuropsychopharmacol 13:199–207

    Article  PubMed  CAS  Google Scholar 

  • Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812

    Article  Google Scholar 

  • Papakostas GI, Fava M (2006) A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry 51:783–790

    Article  PubMed  Google Scholar 

  • Papakostas GI, Stahl SM, Krishen A et al (2008) Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 69:1287–1292

    Article  CAS  PubMed  Google Scholar 

  • Peuskens J, Trivedi J, Malyarov S (2007) Prevention of schizophrenia relapse extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry 4:34–50

    PubMed  PubMed Central  Google Scholar 

  • Porter AMW (1970) Depressive illness in a general practice. A demographic study and a controlled trial of imipramine. BMJ 1:773–778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prien RF, Caffey EM Jr, Klett CJ (1973) Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 28:337–341

    Article  CAS  PubMed  Google Scholar 

  • Prien RF, Klett CJ, Caffey EM Jr (1974) Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 131:198–203

    Article  CAS  PubMed  Google Scholar 

  • Prien RF, Kupfer DJ, Mansky PA et al (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096–1104

    Article  CAS  PubMed  Google Scholar 

  • Raja M, Azzoni A (2003) Comparison of three antipsychotics in the emergency psychiatric setting. Hum Psychopharmacol 18:447–452

    Article  CAS  PubMed  Google Scholar 

  • Rapaport MH, Bose A, Zheng (2004) Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65:44–49

    Article  CAS  PubMed  Google Scholar 

  • Reimherr FW, Byerley WF, Ward MF et al (1988) Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 24:200–205

    Google Scholar 

  • Rösner S, Leucht S, Lehert P et al (2008) Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22:11–23

    Article  PubMed  Google Scholar 

  • Rösner S, Hackl-Herrwerth A, Leucht S (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev (9):CD004332

    Google Scholar 

  • Rösner S, Hackl-Herrwerth A, Leucht S (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (12):CD001867

    Google Scholar 

  • Rummel-Kluge C, Kissling W, Leucht S (2006) Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev (3), Art. No.: CD005581. doi:10.1002/14651858.CD005581.pub2

    Google Scholar 

  • Schäfer I, Lambert M, Naber D (2004) Atypische Antipsychotika bei therapieresistenter Schizophrenie. Nervenarzt 75:79–91

    Article  PubMed  Google Scholar 

  • Schatzberg AF, Cole JO (1978) Benzodiazepines in depressive disorders. Arch Gen Psychiatry 35:1359–1365

    Article  CAS  PubMed  Google Scholar 

  • Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17:675–684

    Article  CAS  PubMed  Google Scholar 

  • Storebø OJ, Krogh HB, Ramstad E et al (2015) Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 351:h5203

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Stuhec M, Munda B, Svab V et al (2015) Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord 178:149–159

    Article  CAS  PubMed  Google Scholar 

  • Taylor DM, Duncan-McConnell D (2000) Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 14:409–418

    Article  CAS  PubMed  Google Scholar 

  • Taylor D, Sparshatt A, Varma S et al (2014) Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 348. doi:10.1136/bmj.g1888

    Google Scholar 

  • Tiihonen J, Haukka J, Taylor M et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609

    Article  PubMed  Google Scholar 

  • Treuer T, Gau SS, Méndez L et al (2013) A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol 23:179–193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 56:1–10

    Article  PubMed  Google Scholar 

  • van den Brink W, Aubin HJ, Bladström A et al (2013) Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 48:570–578

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • van den Brink W, Sørensen P, Torup L et al (2014) Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol 28:733–744

    Article  PubMed  CAS  Google Scholar 

  • van Laar T, De Deyn PP, Aarsland D et al (2011) Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther 17:428–441

    Article  PubMed  CAS  Google Scholar 

  • Vestergaard P, Gram LF, Kragh-Sørensen P et al (1993) Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser 10:190–198

    CAS  PubMed  Google Scholar 

  • Viguera AC, Koukopoulos A, Muzina DJ et al (2007) Teratogenicity and anticonvulsants: lessons from neurology to psychiatry. J Clin Psychiatry 68(Suppl 9):29–33

    PubMed  Google Scholar 

  • Volz HP, Ugur T (2014) Antidepressiva. In: Kasper S, Volz HP (Hrsg) Psychiatrie und Psychotherapie compact, 3. Aufl. Thieme, Stuttgart, S 306–330

    Google Scholar 

  • Volz HP, Gleiter CH, Möller HJ (1996) Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt 67:339–347

    CAS  PubMed  Google Scholar 

  • Volz HP, Reischies F, Riedel M (2010) Kognitive Störungen bei schizophrenen Patienten. Nervenarzt 81:39–54

    Article  PubMed  Google Scholar 

  • Wahlbeck K, Cheine M, Essali A et al (1999) Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials. Am J Psychiatry 156:990–999

    CAS  PubMed  Google Scholar 

  • Warner MD, Peabody CA, Whiteford HA et al (1988) Alprazolam as an antidepressant. J Clin Psychiatry 49:148–150

    CAS  PubMed  Google Scholar 

  • Watanabe N, Omori IM, Nakagawa A et al (2011) Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev (12):CD006528

    Google Scholar 

  • Weinmann S, Roll S, Schwarzbach C et al (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10:14

    Article  PubMed  PubMed Central  Google Scholar 

  • Weisler RH, Nolen WA, Neijber A et al (2011) Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72:1452–1464

    Article  PubMed  Google Scholar 

  • Woodward ND, Purdon SE, Meltzer HY (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457–472

    Article  CAS  PubMed  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782–791

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck, Balthasar-Neumann-Platz 1, 97440, Werneck, Deutschland

    Hans-Peter Volz

  2. Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien AKH, Währinger Gürtel 18-20, 1090, Wien, Österreich

    Siegfried Kasper

  3. em. Direktor der Klinik für Psychiatrie und Psychotherapie der Ludwig-Maximilians-Universität (LMU) München, Nußbaumstr. 7, 80336, München, Deutschland

    Hans-Jürgen Möller

Authors
  1. Hans-Peter Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siegfried Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans-Jürgen Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hans-Peter Volz , Siegfried Kasper or Hans-Jürgen Möller .

Editor information

Editors and Affiliations

  1. em. Direktor der Klinik für Psychiatrie und Psychotherapie, der Ludwig-Maximilians-Universität (LMU) München, München, Germany

    Hans-Jürgen Möller

  2. Ehem. Ärztlicher Direktor des kbo-Inn-Salzach-Klinikums für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Akadem. Lehrkrankenhaus der LMU München Institut für Psychologische Medizin (IPM), Soyen, Germany

    Gerd Laux

  3. Vorstand der Klinik für Psychiatrie und Psychotherapeutische Medizin, Medizinische Universität Graz, Graz, Austria

    Hans-Peter Kapfhammer

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Deutschland

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Volz, HP., Kasper, S., Möller, HJ. (2017). Psychopharmakotherapie – klinisch-empirische Grundlagen. In: Möller, HJ., Laux, G., Kapfhammer, HP. (eds) Psychiatrie, Psychosomatik, Psychotherapie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49295-6_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49295-6_31

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49293-2

  • Online ISBN: 978-3-662-49295-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation